Carticel (autologous cultured chondrocyte) implantation
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Articular Cartilage
Conditions
Articular Cartilage
Trial Timeline
Mar 1, 2000 → Nov 1, 2005
NCT ID
NCT00158613About Carticel (autologous cultured chondrocyte) implantation
Carticel (autologous cultured chondrocyte) implantation is a approved stage product being developed by Vericel for Articular Cartilage. The current trial status is completed. This product is registered under clinical trial identifier NCT00158613. Target conditions include Articular Cartilage.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00158613 | Approved | Completed |
| NCT00140634 | Pre-clinical | Completed |
Competing Products
6 competing products in Articular Cartilage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Abatacept | Bristol Myers Squibb | Phase 3 | 76 |
| Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) | UCB | Phase 3 | 74 |
| autologous cultured chondrocytes on porcine collagen membrane | Vericel | Phase 3 | 72 |
| autologous cultured chondrocytes on porcine collagen membrane | Vericel | Pre-clinical | 18 |
| Carticel (autologous cultured chondrocyte) implantation | Vericel | Pre-clinical | 18 |